Jeil Pharmaceutical Co. Ltd.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. carries a market capitalization of 150.14B, placing it among publicly traded companies globally. Its enterprise value stands at 242.45B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. has 14.70M shares outstanding.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. trades at a trailing price-to-earnings ratio of 16.02. The price-to-sales ratio is 0.27, and the price-to-book ratio stands at 0.73.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 14.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 65.02 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 242.45B versus a market cap of 150.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. maintains a current ratio of 1.33, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.33, indicating elevated leverage, while an interest coverage ratio of 3.57 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jeil Pharmaceutical Co. Ltd. posted a return on equity (ROE) of 4.66, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 1.84, measuring how efficiently the asset base is converted into earnings. The company generates approximately 541.33M in revenue per employee across its workforce of 1,004.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.22 indicates how many times Jeil Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jeil Pharmaceutical Co. Ltd. recorded an income tax benefit of -3.20B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 18.69B, leaving 9.32B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Jeil Pharmaceutical Co. Ltd.'s stock has declined approximately 37.52% over the past 52 weeks. The 50-day moving average sits at 10,059.20, while the 200-day moving average is 12,234.60.

Over the twelve months ended June 30, 2026, Jeil Pharmaceutical Co. Ltd. generated 543.49B in revenue and converted that into 9.32B in net income, yielding earnings per share of 1,497.32. EBITDA reached 16.59B, while operating income came in at 4.08B.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. holds 67.41B in cash and equivalents against 112.28B in total debt, resulting in a net debt position of 51.11B. Total book value stands at 205.81B, with working capital of 81.81B providing operational flexibility.

Jeil Pharmaceutical Co. Ltd. produced -3.08B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.46B in capital expenditures, free cash flow totaled -17.54B - equivalent to -1,199.94 per share.

Over the twelve months ended June 30, 2026, Jeil Pharmaceutical Co. Ltd. posted a gross margin of 40.48, reflecting its pricing power and cost economics. The operating margin of 0.75 and net profit margin of 1.71 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.75: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -13.67, meaning Jeil Pharmaceutical Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Jeil Pharmaceutical Co. Ltd.'s most recent stock split took place on April 11, 2018 with a 5:7 split ratio.

As of June 30, 2026, Jeil Pharmaceutical Co. Ltd. has an Altman Z-Score of 1.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.